Innovent Biologics and Eli Lilly Strike Broad Drug Development Pact
Innovent Biologics has entered a collaboration with Eli Lilly to co-develop new cancer and immune-disease therapies. Innovent will direct research through Phase 2 in China, while Eli Lilly will hold exclusive commercialization rights beyond Greater China. Innovent receives $350 million up front and may collect up to about $8.5 billion in milestone …